Article: Combined Metabolic Activators Improve Mitochondrial Metabolism in Alzheimer's and Parkinson's Disease: Preclinical Findings

PrevNext
Alzheimer's Disease Neurological Health Parkinson's Disease Preclinical

Combined Metabolic Activators Improve Mitochondrial Metabolism in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis

Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are linked to metabolic problems, including mitochondrial dysfunction. This study analyzed human brain data and used animal models of AD and PD to test combined metabolic activators (including nicotinamide riboside). These treatments improved brain and liver tissue health by reducing neuron damage and inflammation caused by a high-fat diet. They also improved motor function in PD rats. Overall, the metabolic activators helped restore mitochondrial metabolism, improved brain and liver function, and show promise as treatments for neurodegenerative diseases.

Journal

Life Sciences

Share

Read more

Clinical

Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Objectives To evaluate if NR could augment neuronal NAD+ levels and impact markers of neurodegeneration and insulin-signaling in plasma-derived human neuronal extracellular vesicles (NEVs). Journa...

Read more
Digestive/Gut Health

Nicotinamide Riboside Protects Intestinal Barrier From Alcohol Damage by Supporting Mitochondrial Function: Preclinical Findings

SynopsisThe intestinal barrier, made up of epithelial tight junctions, prevents harmful substances in the gut from entering the bloodstream. When this barrier is damaged, it can cause widespread in...

Read more